RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer
31 oct. 2023 11h00 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.
Pruritus Therapeutics Market to Reach USD 12.6 Billion by 2032, Poised for Steady 4.1% CAGR
17 oct. 2023 07h15 HE
|
MarketResearch.biz
New York, Oct. 17, 2023 (GLOBE NEWSWIRE) -- According to marketresearch.biz, the estimated size of the global pruritus therapeutics market in 2022 was USD 8.5 billion, and it is expected to exhibit...
ProPhase Labs to Present at The ThinkEquity Conference
12 oct. 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Oct. 12, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, today announced it will be...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
03 oct. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)
03 oct. 2023 08h12 HE
|
Gallant Therapeutics
Gallant Therapeutics and Ethos Discovery collaborate in a clinical study evaluating the use of stem cells to treat pugs with early-stage NME
Albumin Market revenue to cross USD 10 Billion by 2035, says Research Nester
02 oct. 2023 06h30 HE
|
Research Nester
New York, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The global albumin market size is slated to expand at ~ 6% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 10 Billion by the...
Interim results for the six months ended 30 June 2023
29 sept. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
21 sept. 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
18 sept. 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...
Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer
13 sept. 2023 06h53 HE
|
Culture Biosciences
South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences, a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy...